Sumitomo Pharma Co. Ltd (SMDPY PINK) stock market data APIs
$8.0003
0(0%)
as of August 7, 2026
Try our APIs with
free plan!
Sumitomo Pharma Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Prev. Close
8.0003
Open
8.0003
High
8.0003
Low
8.0003
52 wk Range
7.84-24.48
Market Cap
3 600 M
P/E Ratio
4.693
Shares Outstanding
449 M
Revenue
474 787 M
EPS
0.2448
Beta
0.457
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sumitomo Pharma Co. Ltd data using free add-ons & libraries
Get Sumitomo Pharma Co. Ltd Fundamental Data
Sumitomo Pharma Co. Ltd Fundamental data includes:
- Net Revenue: 474 787 M
- EBITDA: 68 338 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-06-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sumitomo Pharma Co. Ltd News
New
Sumitomo Chemical Co Ltd (SOMMF) (Q1 2027) Earnings Call Highlights: Core Operating Income ...
This article first appeared on GuruFocus. Revenue: Consolidated sales revenue was JPY578.2 billion, up JPY52.1 billion year on year. Core Operating Income: Increased significantly to JPY62.3 billion,...
Sumitomo Pharma Co., Ltd. GAAP EPS of ¥ 39.02, revenue of ¥ 129.4B
* Sumitomo Pharma Co., Ltd. press release [https://www.sumitomo-pharma.com/ir/library/financial_results_summary/assets/pdf/ebr20260731_1.pdf] (SMDPY [https://seekingalpha.com/symbol/SMDPY]): Q1 GAAP...
Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements
Consolidated net sales of TWYMEEG® in Japan for the2nd quarter of 2026 reached 2.9 billion yen (15.5 million euros1), up 32 per cent compared with the 2nd quarter of 2025. Consolidated net sales of T...
Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia
– Orphan drug designation was previously granted to enzomenib for acute myeloid leukemia in June 2022 – Enzomenib is being evaluated in an ongoing Phase 1/2 dose-escalation/dose-expansion study i...
Get Sumitomo Pharma Co. Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
